Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients

This study has been completed.
Information provided by:
Chimerix Identifier:
First received: July 17, 2009
Last updated: January 16, 2012
Last verified: January 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):